Funding

Supported by Dermavant Sciences, Inc. Medical writing and editorial assistance were funded by Dermavant Sciences, an Organon Company.

Conflict of interest

Amy S. Paller is an investigator, without personal compensation, for AbbVie, Applied Pharma Research, Biomendics, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron, Timber, and UCB Pharma; a consultant (with honoraria) for Abeona, Apogee, Arcutis, Aslan, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Dermavant Sciences, Inc., Incyte, Krystal Biotech, LEO Pharma, L’Oreal, Mitsubishi Tanabe, MoonLake Immunotherapeutics, Procter & Gamble, Regeneron, Sanofi/Genzyme, Seanergy, and UCB Pharma; and on the Data Safety Monitoring Board for AbbVie, Abeona, and Galderma. Amy S. Paller is an Editorial Board member of the American Journal of Clinical Dermatology; she was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Adelaide A. Hebert is an investigator without personal compensation for research support for AbbVie, Amgen, Arcutis, Dermavant Sciences, Inc., and Pfizer; and has received honoraria from Arcutis, Almirall, Incyte, LEO Pharma, Mayne, Novan, Pfizer, and Verrica; and is on Data Safety Monitoring Boards for GSK, Ortho Dermatologics, and Sanofi Regeneron. Mercedes E. Gonzalez has been an investigator for AbbVie, Arcutis, Amgen, Anterogen, Dermavant Sciences, Inc., Eli Lilly, Incyte, Krystal Biotech, Neilsen Biosciences, Novartis, Pfizer, Regeneron, Sanofi/Genzyme; a consultant with honorarium for Abeona, Arcutis, Alphyn, Apogee, Chiesi, Dermavant Sciences, Inc., Eli Lilly, Galderma, Incyte, Kenvue, Krystal Biotech, LEO Pharma, Pelthos Therapeutics, and Verrica; and on the speakers bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Krystal Biotech, LEO Pharma, Pfizer, Regeneron, Sanofi/Genzyme, and Verrica. Victoria Butners, Glenn Tabolt, and David S. Rubenstein are former employees of Dermavant Sciences, Inc. Nancy Fitzgerald and Stephen C. Piscitelli are employees of Dermavant Sciences, an Organon Company.

Data availability

The data that support the findings of the trials and studies are proprietary and are not publicly available. The data may be made available upon reasonable request and with permission from Dermavant Sciences, an Organon Company, but restrictions will apply to the availability of these data.

Ethics approval

The trial was approved by the central Institutional Review Board, Advarra (July 30, 2021), and conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation guidelines, Good Clinical Practice, and local applicable regulatory requirements.

Informed consent

Written informed consent was obtained from all patients and/or their parents/legal guardians prior to the start of trial treatment.

Patient consent to publish

Not applicable.

Code availability

Not applicable.

Author contributions

Stephen C. Piscitelli wrote the first draft, and all authors contributed to the critical revision of the manuscript. All authors have read and approved the final version of the manuscript.